Article Per Year (5 Year)
p-Index From 2021 - 2026
0.702
P-Index
This Author published in this journals
All Journal WAJAH HUKUM Pharmacoscript
Muhammad, Fauzi
Unknown Affiliation
Chemistry Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Pharmacoscript

 1 
CHARACTERIZATION AND ANTIOXIDANT ACTIVITY OF KALAKAI (Stenochlaena palustris) LEAVES EXTRACT IN NANOSTRUCTURED LIPID CARRIER SYSTEM Fahrina, Nurhaliza; Aris, Fadillah; Muhammad, Fauzi
Pharmacoscript Vol. 8 No. 1 (2025): Pharmacoscript
Publisher : Lembaga Penelitian dan Pengabdian Masyarakat, Universitas Perjuangan Tasikmalaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36423/pharmacoscript.v8i1.2066

Abstract

Exposure to ultraviolet light can cause damage and death of skin cells through multiple mechanisms, including the formation of free radicals that can cause hyperpigmentation, erythema, sunburn, photo-aging, and even skin cancer. Kalakai (Stenochlaena palustris) is a typical Kalimantan plant with the ability to be a high antioxidant. However, it is still very rarely utilized. Kalakai leaves contain polyphenolic groups that function as free radical antidotes, as well as flavonoid compounds that can stabilize radical compounds. Various technology-based drug delivery systems have been developed to improve therapeutic effectiveness, including nanotechnology. Nanostructured lipid carrier (NLC) is the second-generation lipid-based carrier designed to overcome the limitations of previous-generation lipid-based carriers. This system consists of a mixture of and unstructured due to their different constituent parts. This research will develop a formula for kalakai leaf extract in a nanostructured lipid carrier system using the emulsification-sonication method. Based on the data, the characteristics of kalakai leaf extract in a nanostructured lipid carrier system that meet the standards are F1 (5%) and F2 (10%). Among the three formulas, F3 showed the highest IC50 value compared to F1 and F2, which is 14,967 ± 0,240 with powerful antioxidant activity, followed by F2 with an IC50 value of 24,186 ± 1,797, and F1 with IC50 value of 65,504 ± 5,041.
SEVERITAS INTERAKSI OBAT CLOZAPINE PADA PASIEN SKIZOFRENIA: ANALISIS KARAKTERISTIK Siska, Lidiya; Muhammad, Fauzi; Juwita, Ramadhani; Karina, Erlianti
Pharmacoscript Vol. 8 No. 2 (2025): Pharmacoscript
Publisher : Lembaga Penelitian dan Pengabdian Masyarakat, Universitas Perjuangan Tasikmalaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36423/pharmacoscript.v8i2.2110

Abstract

Skizofrenia merupakan gangguan mental kronis yang memerlukan penanganan farmakologis, seringkali melibatkan penggunaan clozapine sebagai terapi lini akhir. Penelitian ini bertujuan untuk mengidentifikasi keparahan interaksi obat pada penggunaan clozapine dan menganalisis karakteristik pasien skizofrenia yang mempengaruhi interaksi obat di Rumah Sakit Jiwa Daerah (RSJD) Sambang Lihum. Penelitian ini menggunakan desain cross-sectional dengan pendekatan retrospektif. Rekam medis pasien skizofrenia yang memenuhi kriteria inklusi dan eksklusi dipilih secara purposive dari data tahun 2023. Analisis dilakukan dari 100 pasien ditemukan 96 pasien memiliki potensi interaksi obat. Mayoritas interaksi (78%) tergolong farmakodinamik dengan 72 kasus berada pada tingkat keparahan mayor. Obat yang paling sering berinteraksi dengan clozapine antara lain haloperidol, lorazepam, trifluoperazine, trihexyphenidyl, dan chlorpromazine. Karakteristik pasien terdiri dari pasien skizofrenia yang menggunakan clozapine mayoritas berjenis kelamin laki-laki (66%), berusia 26–45 tahun (68%), tidak bekerja (79%), berpendidikan maksimal SD (40%), dan telah menjalani terapi selama < 5 – 10 tahun (83%). Hasil analisis menunjukkan interaksi farmakodinamik pada tingkat keparahan mayor sering terjadi pada pasien skizofrenia. Faktor usia berhubungan signifikan terhadap potensi interaksi obat ( ) dimana pasien usia > 45 tahun memiliki kemungkinan 1.262 kali lebih besar mengalami interaksi obat katagori mayor dibandingkan pasien < 45 tahun. Temuan ini menunjukkan perlunya diperhatikan faktor usia dalam optimalisasi terapi clozapine guna mengurangi risiko efek samping akibat interaksi obat.
Co-Authors Aris Fadillah Daud, Sulhi Muhmad Fahrina, Nurhaliza Juwita, Ramadhani Karina, Erlianti Mukhtar Latif Siska, Lidiya